+65 63464191 info@healthytimes.com.sg
Health Magazine Singapore l Singapore Health Magazine l Healthy Times Magazine
  • Home
  • Health
  • Fitness
  • Beauty
  • Food & Nutrition
  • Green Living
  • Kids & Women
  • Disease and Prevention
  • Well Being
  • Events
  • Bahasa
Select Page

Tycoon Group Sustains Profitability: 2026 Interim Results Net Profit Surges 183% Year-on-Year

by | PRNewswire Asia

Business Demonstrates Strong Resilience, Profitability Continues to Materialise Results Highlights Tycoon Group sustained its turnaround success from the previous year, recording a net profit of approximately HK$6.3 million during the Period (1H2025: net loss of...

LifeTech Scientific Corporation Announces 2026 Interim Results

by | PRNewswire Asia

HONG KONG, Aug. 29, 2026 /PRNewswire/ — LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally...

Fosun International: ClubMed Lifestyle Group Submits Listing Application to the Hong Kong Stock Exchange

by | PRNewswire Asia

ClubMed Lifestyle Group’s revenue reached EUR1.95 billion in 2025. Adjusted EBITDA reached EUR 390 million in 2025, with the adjusted EBITDA margin rising to 20.2% in 2025. ClubMed Lifestyle Group expects to operate approximately 85 resorts worldwide by 2030....

GS1 HK Food Safety Forum 2026 Spotlights Traceability and Sustainability

by | PRNewswire Asia

Building a Trusted Food Ecosystem with Technology, Data and Standards HONG KONG, Aug. 28, 2026 /PRNewswire/ — Organised by GS1 Hong Kong (GS1 HK), the 12th Food Safety Forum was held today, bringing together 300 professionals from the food and beverage sector to...

Leifras Celebrates 25th Anniversary, Setting Vision for Becoming Global Infrastructure Through "Sports and Social"

by | PRNewswire Asia

Operating Across All 47 Prefectures in Japan, Ranking No. 1 in School Club Activity Support (According to Tokyo Shoko Research, as of December 2025) with Over 70,000 Sports School Members. Following Its Nasdaq Listing, Leifras Sets Vision for the Next 25 Years to...

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

by | PRNewswire Asia

TSY-110 is positioned to become the first biosimilar alternative to Roche’s Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ — Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission...
« Older Entries
Next Entries »
  • Beauty
  • Disease and Prevention
  • Events
  • Fitness
  • Food and Nutrition
  • Green Living
  • Health
  • Kids and Women
  • News
  • Well Being

PRNewswire Asia

Sitemap

Links

editor@healthytimes.com.sg

editor@healthytimes.com.sg (Press Release)

Phone:+65 63464191

  • Facebook
© Copyright healthytimes.com.sg